RecruitingPhase 3

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

France1,164 participantsStarted 2023-08-02

Plain-language summary

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Nulliparous women aged 18 years or more * Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor * Singleton pregnancy * Evolutive pregnancy between 9 and 14 weeks of gestation * Women affiliated to a French Social Security Insurance or equivalent social protection * Written informed consent Exclusion Criteria: * Major fetal abnormality * Regular treatment with aspirin (including antiphospholipid syndrome) * Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia) * Women protected by law. * Women included in another interventional study.

What they're measuring

Effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo in the prevention of preterm (<37 weeks of gestation) preeclampsia

Timeframe: Up to 9 months

Trial details

NCT IDNCT05625724

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-08

Contact for this trial

Paul GUERBY, MD

5 67 77 12 33 guerby.p@chu-toulouse.fr

View on ClinicalTrials.gov More ART trials